Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;15:3105–3122. doi: 10.2147/COPD.S273497

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tashkin.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Time to first moderate or severe exacerbation^a in the RISE study.

Notes:^aBetween-treatment difference in time to first moderate or severe exacerbation, p<0.016; Cox regression model. Reprinted from Respiratory Medicine, Vol 132, Ferguson et al, Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study, pages 31–41, Copyright 2017, with permission from Elsevier.²¹

Abbreviations: B/f, budesonide/formoterol; BID, twice daily; DPI, dry powder inhaler; f, formoterol; pMDI, pressurized metered-dose inhaler.